Ratings Mankind Pharma Limited

Equities

MANKIND

INE634S01028

Market Closed - NSE India S.E. Other stock markets 05:17:54 21/06/2024 pm IST			5-day change	1st Jan Change
2,166 ^INR	-1.35%		-3.31%	+9.27%

03/06	Mankind Pharma Limited Receives Order from Office of Superintendent of Central Tax, Bholakpur, Telangana	CI
30/05	Advent International Receives 6-7 Bids for Bharat Serums	CI

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 50% by 2026.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.38 times its estimated earnings per share for the ongoing year.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
MANKIND PHARMA LIMITED	+9.27%	1.04TCr	-
ELI LILLY AND COMPANY	+51.63%	80TCr	C+
NOVO NORDISK A/S	+41.51%	63TCr	B
JOHNSON & JOHNSON	-5.10%	36TCr	C+
MERCK & CO., INC.	+19.90%	33TCr	B-
ABBVIE INC.	+9.95%	30TCr	C+
ASTRAZENECA PLC	+17.66%	24TCr	B+
ROCHE HOLDING AG	+3.39%	23TCr	A+
NOVARTIS AG	+10.75%	21TCr	B-
AMGEN INC.	+6.99%	17TCr	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes